勘误：LHX6通过抑制Wnt/β-连环蛋白信号通路影响表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）耐药性及人非小细胞肺癌HCC827细胞迁移[勘误说明] 。
Erratum: LHX6 Affects Erlotinib Resistance and Migration of -Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum].
出版信息
Onco Targets Ther. 2021 Jan 12;14:253. doi: 10.2147/OTT.S299935. eCollection 2021.
Abstract
[This corrects the article DOI: 10.2147/OTT.S258896.].
摘要
[本文更正了文章的数字对象标识符：10.2147/OTT.S258896。]
相似文献
1
Erratum: LHX6 Affects Erlotinib Resistance and Migration of -Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum].勘误：LHX6通过抑制Wnt/β-连环蛋白信号通路影响表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）耐药性及人非小细胞肺癌HCC827细胞迁移[勘误说明] 。
Onco Targets Ther. 2021 Jan 12;14:253. doi: 10.2147/OTT.S299935. eCollection 2021.
2
Erratum: LHX6 Affects Erlotinib Resistance and Migration of -Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum].勘误：LHX6通过抑制Wnt/β-连环蛋白信号通路影响表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）耐药性及人EGFR1基因敏感突变非小细胞肺癌HCC827细胞的迁移[更正] 。
Onco Targets Ther. 2021 Apr 6;14:2337. doi: 10.2147/OTT.S313313. eCollection 2021.
3
LHX6 Affects Erlotinib Resistance and Migration of -Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling.LHX6通过抑制Wnt/β-连环蛋白信号通路影响表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）耐药及人非小细胞肺癌HCC827细胞迁移
Onco Targets Ther. 2020 Oct 28;13:10983-10994. doi: 10.2147/OTT.S258896. eCollection 2020.
4
Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.下调 miR-214 通过上调 LHX6 表达逆转非小细胞肺癌对厄洛替尼的耐药性。
Sci Rep. 2017 Apr 10;7(1):781. doi: 10.1038/s41598-017-00901-6.
5
Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.孕激素受体膜成分 1 导致厄洛替尼耐药，启动肺腺癌细胞中 Wnt/β-连环蛋白和 NF-κB 通路的串扰。
Sci Rep. 2020 Mar 16;10(1):4748. doi: 10.1038/s41598-020-61727-3.
6
The Role of in Erlotinib Resistance: Activation of the //β- Signaling Pathway.在厄洛替尼耐药中的作用：//β信号通路的激活。
（你提供的原文中存在一些不完整的表述，可能会影响准确理解，你可以检查并补充完整后再让我翻译。）
Front Oncol. 2020 Oct 28;10:585292. doi: 10.3389/fonc.2020.585292. eCollection 2020.
7
[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].表皮生长因子受体突变型非小细胞肺癌细胞系H1650中厄洛替尼耐药的分子机制
Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):689-93. doi: 10.3779/j.issn.1009-3419.2012.12.02.
8
Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/ pathway.非小细胞肺癌对厄洛替尼的敏感性受Notch/miR-223/信号通路调控。
Biosci Rep. 2017 Jun 21;37(3). doi: 10.1042/BSR20160478. Print 2017 Jun 30.
9
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.IGF1R缺失促进MET扩增，作为HCC827非小细胞肺癌细胞对厄洛替尼获得性耐药的机制。
Oncotarget. 2017 May 16;8(20):33300-33315. doi: 10.18632/oncotarget.16350.
10
Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.EGFR-TKI 耐药细胞系 HCC827-TR 中获得性耐药的分子机制。
Thorac Cancer. 2020 May;11(5):1129-1138. doi: 10.1111/1759-7714.13342. Epub 2020 Mar 12.
引用本文的文献
1
Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC.立体定向放疗联合卡瑞利珠单抗治疗晚期 NSCLC 的协同效应。
J Healthc Eng. 2022 Mar 8;2022:7875627. doi: 10.1155/2022/7875627. eCollection 2022.
Zotero 插件